HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology.
HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology. The company's technology platforms and products cover a wide range of immunotherapy modalities and mechanisms of action, including innate immunity activation, adaptive immune response amplification, and tumor-tight junction disruption. Its mission is to maintain the rapid and significant progress made in the fight against the world's deadliest infectious diseases by developing cutting-edge immunotherapy technologies in a cost-effective manner across leading markets as well as low or middle-income countries.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 30, 2022 | Grant | $49M | 1 | Medical CBRN Defense Consortium | — | Detail |
Aug 8, 2022 | Grant | $1.80M | 1 | US Army | — | Detail |
May 17, 2021 | Grant | $2.90M | 1 | National Institutes of Health | — | Detail |
Oct 5, 2020 | Seed | $6M | 2 | Zoic Capital | — | Detail |
Sep 1, 2020 | Grant | $8.25M | 1 | National Institute of Allergy and Infectious Diseases | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Medical CBRN Defense Consortium | Yes | Grant |
US Army | Yes | Grant |
National Institutes of Health | Yes | Grant |
Zoic Capital | Yes | Seed |
National Institute of Allergy and Infectious Diseases | Yes | Grant |
Eric Anschutz | — | Seed |